Aortic Stenosis Prognosis | New Heart Valve HCP

Prosthesis-patient mismatch (PPM) is associated with increased mid-term and long-term mortality rates after aortic valve replacement (AVR). This study aimed to evaluate the efficacy of the Carpentier-Edwards Perimount Magna and Magna Ease (CEPMs) aortic bioprostheses to reduce the incidence of PPM.

Surgical mitral pericardial valves | Edwards Lifesciences

Utilizes the same bovine pericardial tissue (from a cow's heart) as Edwards surgical valves

How a prosthesis in aortic valve replacement is chosen

The long-term results of aortic valve replacement (AVR; n=737) with bileaflet mechanical prosthesis (MP) or Carpentier-Edwards Perimount bioprostheses (BP) were evaluated in different age groups.

Aortic Ball-Valve (Starr-Edwards) Prostheses: A Follow …

Aortic valve replacement (AVR) with a bioprosthesis is standard therapy for severe aortic stenosis, even in the era of transcatheter AVR (TAVR).,Older Asian people tend to be short in stature, and their aortic annulus is smaller than usual, proportionate to their body size. A previous study found that operative mortality generally decreased with increasing body surface area (BSA).Another problem in patients with a larger BSA and a small annulus is prosthesis-patient mismatch (PPM).,A previous study showed that the effect of PPM on mortality was greater in patients It has been suggested that PPM has a significant effect on short-term and long-term outcomes.

EDWARDS INTUITY Elite valve system Aortic valve, model 8300AB & delivery system, model 8300DB

Healing Around the Starr-Edwards Aortic Valve Prosthesis in Patients

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

Carpentier-Edwards PERIMOUNT Magna aortic valve ..

The Edwards SAPIEN XT transcatheter heart valve, model 9300TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Find all the manufacturers of aortic valve prosthesis and contact them directly on MedicalExpo.

Edwards Lifesciences’ newest aortic valve demonstrates …

This study involved human subjects and was reviewed and approved by the Institutional Review Board at Kyushu University. Between 4 November 1981 and 16 December 2013, 737 patients underwent AVR excluding aortic root replacement with bileaflet MP (n=424) or CEP BP (Edwards Lifesciences, Irvine, CA, USA, n=313). In the bileaflet MP group, CarboMedics valve (CarboMedics; Austin, TX, USA) was used in 184 patients, St. Jude Medical valve (SJM; St. Jude Medical, Minneapolis, MN, USA) was used in 230 patients and ATS valve (ATS Medical, Minneapolis, MN, USA) was used in 10 patients. We used 39 stentless BP (14 Toronto Stentless Porcine Valve and 25 Medtronic Freestyle) during the 1994–2004 period, and 20 Mitroflow BP have been used since April 2013 for AVR. Because the design and the hemodynamic performance of theses stentless BP and Mitroflow BP are different from CEP stented BP, we excluded the stentless BP and Mitroflow BP results from the present study. With regard to prosthesis selection, we explained and discussed the merits and demerits of both prostheses (BP and MP) with the patients before AVR, and the patients themselves decided on prosthesis type. This prosthesis selection procedure has been followed consistently throughout the last 30 years at Kyushu University. The predominant causes of valve disease were rheumatic or degenerative heart disease in all groups (). There were no significant differences in the logistic EuroSCORE or the number of concomitant cardiac procedures between the 2 groups (MP or BP) for each age group ().

5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis

a previously implanted aortic valve prosthesis which is no longer ..

The Edwards SAPIEN 3 transcatheter heart valve will be placed on the delivery system and compressed on a balloon. The delivery system carrying the valve will be placed through the sheath and delivered to your aortic valve. The balloon of the delivery system will be inflated, expanding the new valve within your diseased valve.